NASDAQ: PMN
Promis Neurosciences Inc Stock

$0.62+0.04 (+6.9%)
Updated Apr 30, 2025
PMN Price
$0.62
Fair Value Price
N/A
Market Cap
$20.27M
52 Week Low
$0.51
52 Week High
$2.37
P/E
5.64x
P/B
1.23x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$2.78M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.15
Operating Cash Flow
-$27M
Beta
0.35
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A

PMN Overview

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine PMN's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
PMN
Ranked
Unranked of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important PMN news, forecast changes, insider trades & much more!

PMN News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PMN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PMN is good value based on its earnings relative to its share price (5.64x), compared to the US market average (29.18x)
P/E vs Market Valuation
PMN is good value based on its earnings relative to its share price (5.64x), compared to the US Biotechnology industry average (-162.28x)
P/E vs Industry Valuation
PMN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more PMN due diligence checks available for Premium users.

Valuation

PMN fair value

Fair Value of PMN stock based on Discounted Cash Flow (DCF)

Price
$0.62
Fair Value
$0.95
Undervalued by
34.44%

PMN price to earnings (PE)

For valuing profitable companies with steady earnings

Company
5.64x
Industry
-162.28x
Market
29.18x
PMN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PMN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

PMN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.23x
Industry
4.45x
PMN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PMN's financial health

Profit margin

Revenue
$0.0
Net Income
-$238.2k
Profit Margin
0%
PMN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$18.9M
Liabilities
$2.4M
Debt to equity
0.15
PMN's short-term assets ($18.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PMN's short-term assets ($18.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PMN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$8.7M
Investing
$0.0
Financing
$470.0k
PMN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PMN vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
PMN$20.27M+6.35%5.64x1.23x
PASG$20.26M+4.49%-0.30x0.33x
VYNED$20.23M-5.67%-1.43x0.39x
LEXX$20.37M-0.85%-1.97x2.85x
ALLRD$20.42M+5.26%-0.08x1.73x

Promis Neurosciences Stock FAQ

What is Promis Neurosciences's quote symbol?

(NASDAQ: PMN) Promis Neurosciences trades on the NASDAQ under the ticker symbol PMN. Promis Neurosciences stock quotes can also be displayed as NASDAQ: PMN.

If you're new to stock investing, here's how to buy Promis Neurosciences stock.

What is the 52 week high and low for Promis Neurosciences (NASDAQ: PMN)?

(NASDAQ: PMN) Promis Neurosciences's 52-week high was $2.37, and its 52-week low was $0.51. It is currently -73.84% from its 52-week high and 21.33% from its 52-week low.

How much is Promis Neurosciences stock worth today?

(NASDAQ: PMN) Promis Neurosciences currently has 32,689,190 outstanding shares. With Promis Neurosciences stock trading at $0.62 per share, the total value of Promis Neurosciences stock (market capitalization) is $20.27M.

Promis Neurosciences stock was originally listed at a price of $9.25 in Jul 8, 2022. If you had invested in Promis Neurosciences stock at $9.25, your return over the last 2 years would have been -93.3%, for an annualized return of -74.11% (not including any dividends or dividend reinvestments).

How much is Promis Neurosciences's stock price per share?

(NASDAQ: PMN) Promis Neurosciences stock price per share is $0.62 today (as of Apr 30, 2025).

What is Promis Neurosciences's Market Cap?

(NASDAQ: PMN) Promis Neurosciences's market cap is $20.27M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Promis Neurosciences's market cap is calculated by multiplying PMN's current stock price of $0.62 by PMN's total outstanding shares of 32,689,190.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.